Accenture teams up with Bayer for speedier drug development

German pharma Bayer joins a host of companies in trying to simplify and speed up the journey from bench to bedside, penning a deal with services company Accenture to help do just that.

The New York-headquartered firm has signed up to help Bayer by using its so-called INTIENT Clinical platform.

How does it work? In a nutshell, it brings internal and external clinical data together with Oracle’s cloud-based tech into a single data management and warehousing platform, “creating actionable insights to accelerate drug development and improve patient outcomes,” according to the joint release. INTIENT works alongside the technology giant.

RELATED: Bayer nabs new dealmaker—but after Monsanto, is there enough cash?

Mike Stapleton, a managing director in Accenture’s Life Sciences practice, said: “We are excited to work with Bayer to provide new insights on their clinical trials, so they can bring the important treatments they develop to patients faster and with the highest quality. The future of R&D is bright when leading organizations come together to solve for patients’ greatest needs.”

Financial details of the pact were not disclosed.